No results

EQT to sell Ellab to Novo Holdings

EQT to sell Ellab to Novo Holdings

Today, EQT announced they have agreed to sell Ellab to Novo Holdings, a leading global life sciences investor.


Ellab’s portfolio of high-quality offerings for the pharma and biotech sector aligns perfectly with Novo Holdings investment focus and expertise, and Novo Holdings will support the continued growth of Ellab, building on the impressive long-standing track-record, by utilizing its industry network and global presence to accelerate future business expansion.


CEO of Ellab A/S, Ludvig Enlund commented:

“Today is a proud day for Ellab. Our company has seen tremendous growth under EQT’s ownership; tripling our revenue, EBITDA and number of employees, and this transaction is a culmination of that. We have been grateful for the partnership with EQT and now look forward to continuing our journey with Novo Holdings to ensure the continued success of Ellab and our long-term strategy”.

Financial terms of the transaction are not disclosed. The transaction is subject to regulatory approval, and closing of the transaction is expected in Q3 2023.

Reference is made to the press release from EQT (link) and Novo Holdings (link).


From left to right: Ludvig Enlund, CEO at Ellab, Andreas Morthorst, CFO at Ellab


For further information, please contact:

Jan Fledelius, Vice President, Global HR & Communications, phone
+45 42460200 or

About Ellab

Headquartered in Hillerød, Denmark, Ellab provides mission-critical Validation- and Monitoring Solutions and Services used for measuring and documenting critical parameters such temperature, pressure and CO2 in mainly biotech and pharma processes. The Company serves all of the top 20 biotech companies and all of the top 40 pharma companies globally, helping them ensure consumer safety and regulatory compliance, while reducing time to market and the risk of product loss.

More info:

About EQT

EQT is a purpose-driven global investment organization with EUR 119 billion in assets under management within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia-Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info:

About Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio, with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

More info:

Learn more about exciting news from the world of Ellab.

Do you have a question?

Do you have a question?